Rns7 Jul 2022 12:27
Hi captain swag been busy working if I was included in your Mia post
This should have been Rns'd not tweeted
Lastly, the Company has launched a new lateral flow test (LFT) reader for use in conjunction with a number of key assays within Novacyt's Pathflow® product portfolio. The small, lightweight LFT reader instrument is designed to provide digital test results based on optical imaging technology thereby removing the ambiguity of manually interpreting a positive/negative reading. The result is available in a matter of seconds (~10-12 secs) in a digital form that can be exported to other systems.
Excellent why bother though
This should have been Rns I mean it's approx 7 per cent of current quarterly revenues
In line with Novacyt's strategy to maintain its position as a global first responder, the Company launched a research-use-only (RUO) monkeypox PCR assay and is developing an RUO assay for adenovirus F Type 41. In addition, the Company has signed a contract with a leading global non-governmental organisation (NGO) to support the detection of arboviruses, including dengue, Zika and Chikungunya, with the total value of the first order approximately £220,000.
Another Rns below
Novacyt has also strengthened its position as an integrated reagent and instrument solution provider by signing an agreement with a leading global health provider to supply both instruments and reagents, for the detection of infectious diseases including high risk HPV and HIV, over a three year period.
Great again why not?
Following should have been Rns reach
Novacyt has advanced the product design of two new polymerase chain reaction (PCR) assays for near-patient testing in infectious diseases. These new assays are focused on gastro-intestinal viruses and bacteria and will run on the Company's q32 instruments. In addition, the Company has developed three single analyte transplant viral panels for use on open instrument platforms. Two of the transplant assays are complete and the final CMV assay has been filed for regulatory approval, in line with product development plans as outlined in 2021 full year results.
Could they possibly be more negative in the first paragraph I doubt it.
Pil you won't go away but stop pretending you are invested quick quick type an answer
Must get to the top of the page.... I done a hashtag last night re board of directors my goodness I was polite with it.
Remember cabbage patch dolls.
Saying all that I will probably buy some more as the science is great and they will win. Gla holders.
Sign In
Follow the stocks
